K
Kendal Redmond
Researcher at Princess Alexandra Hospital
Publications - 10
Citations - 768
Kendal Redmond is an academic researcher from Princess Alexandra Hospital. The author has contributed to research in topics: Medicine & Tenecteplase. The author has an hindex of 4, co-authored 6 publications receiving 382 citations.
Papers
More filters
Journal ArticleDOI
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
Bruce C.V. Campbell,Peter Mitchell,Leonid Churilov,Nawaf Yassi,Timothy Kleinig,Richard Dowling,Bernard Yan,Steven Bush,Helen M Dewey,Vincent Thijs,Vincent Thijs,Rebecca Scroop,Marion Simpson,Mark Brooks,Hamed Asadi,Hamed Asadi,Hamed Asadi,Teddy Y. Wu,Teddy Y. Wu,Darshan Shah,Darshan Shah,Tissa Wijeratne,Timothy Ang,Ferdinand Miteff,Christopher R Levi,Edrich Rodrigues,Henry Zhao,Patrick Salvaris,Carlos Garcia-Esperon,Peter L. Bailey,Henry E. Rice,Laetitia de Villiers,Helen Brown,Kendal Redmond,David Leggett,John N. Fink,Wayne Collecutt,Andrew Wong,Claire Muller,Alan Coulthard,Ken Mitchell,John Clouston,Kate Mahady,Deborah Field,Henry Ma,Thanh G. Phan,Winston Chong,Ronil V. Chandra,Lee-Anne Slater,Martin Krause,Timothy Harrington,Timothy Harrington,Kenneth Faulder,Kenneth Faulder,Brendan Steinfort,Brendan Steinfort,Christopher F. Bladin,Christopher F. Bladin,Gagan Sharma,Patricia Desmond,Mark W Parsons,Geoffrey A. Donnan,Stephen M. Davis +62 more
TL;DR: Tenecteplase before thrombectomy was associated with a higher incidence of reperfusion and better functional outcome than alteplase among patients with ischemic stroke treated within 4.5 hours after symptom onset.
Journal ArticleDOI
Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK Part 2 randomized clinical trial
Bruce C.V. Campbell,Bruce C.V. Campbell,Peter Mitchell,Leonid Churilov,Leonid Churilov,Leonid Churilov,Nawaf Yassi,Nawaf Yassi,Nawaf Yassi,Timothy Kleinig,Richard Dowling,Bernard Yan,Steven Bush,Vincent Thijs,Vincent Thijs,Rebecca Scroop,Marion Simpson,Mark Brooks,Hamed Asadi,Hamed Asadi,Hamed Asadi,Teddy Y. Wu,Darshan Shah,Tissa Wijeratne,Henry Zhao,Fana Alemseged,Felix C Ng,Peter L. Bailey,Henry E. Rice,Laetitia de Villiers,Helen M Dewey,Philip M. C. Choi,Helen Brown,Kendal Redmond,David Leggett,John N. Fink,Wayne Collecutt,Thomas Kraemer,Martin Krause,Dennis Cordato,Deborah Field,Henry Ma,Bill O'Brien,Benjamin Clissold,Ferdinand Miteff,Anna Clissold,Geoffrey Cloud,Leslie E. Bolitho,Luke Bonavia,Arup Bhattacharya,Alistair Wright,Abul Mamun,Fintan O'Rourke,John M. Worthington,Andrew Wong,Christopher Levi,Christopher F. Bladin,Christopher F. Bladin,Christopher F. Bladin,Gagan Sharma,Patricia Desmond,Mark W Parsons,Geoffrey A. Donnan,Stephen M. Davis +63 more
TL;DR: Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy, and the findings suggest that the0.40-mg/kg dose ofTenecte Plase does not confer an advantage over the 0.25-mg-kg dose.
Journal ArticleDOI
Endovascular thrombectomy versus standard bridging thrombolytic with endovascular thrombectomy within 4·5 h of stroke onset: an open-label, blinded-endpoint, randomised non-inferiority trial
Peter Mitchell,Bernard Yan,Leonid Churilov,Richard Dowling,Steven Bush,Andrew Bivard,Xiao Huo,Guoqing Wang,Shiyong Zhang,Mai Duy Ton,Dennis Cordato,Timothy Kleinig,Henry Hin Kui Ma,Ronil V. Chandra,Helen Brown,Bruce C.V. Campbell,Andrew Cheung,Brendan Steinfort,Rebecca Scroop,Kendal Redmond,F. Miteff,Yang Liu,Dang Phuc Duc,Henry E. Rice,Mark W Parsons,Teddy Y. Wu,Huy Thang Nguyen,Geoffrey A. Donnan,Zhongrong Miao,Stephen M. Davis,Patricia Desmond,Nawaf Yassi,Henry Zhao,Cameron Williams,Fana Alemseged,Felix C Ng,Vignan Yogendrakumar,Peter L. Bailey,L. de Villiers,Thanh G. Phan,Tharani Thirugnanachandran,Winston Chong,Hamed Asadi,Lee-Anne Slater,Nathan W Manning,Jason Wenderoth,Alan McDougall,Cecilia Cappelen-Smith,Justin T. Whitley,Leon Edwards,Carlos Garcia-Esperon,Neil J. Spratt,Elizabeth Pepper,Christopher R Levi,Kenneth Faulder,Timothy Harrington,Martin Krause,Michael J. Waters,J. Fink,Gaoting Ma,Xiangpeng Shen,Xiang-jun Song,Yong-jian Gao,Nam Guangxian,Zaiyu Guo,Heliang Zhang,Hongxing Han,Hao Wang,Geng Liao,Zhenyu Zhang,Chaomao Li,Zhihua Yang,Chuwei Cai,Chuming Huang,Yifan Hong +74 more
TL;DR: The clinical outcomes of patients with stroke with large vessel occlusion treated with direct endovascular thrombectomy within 4·5 h would be non-inferior compared with the outcomes of those treated with standard bridging therapy, as well as the intention-to-treat population, were hypothesized.
Journal ArticleDOI
Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): A multicenter, randomized, controlled study
Bruce C.V. Campbell,Peter Mitchell,Leonid Churilov,Nawaf Yassi,Nawaf Yassi,Timothy Kleinig,Bernard Yan,Richard Dowling,Steven Bush,Helen M Dewey,Vincent Thijs,Vincent Thijs,Marion Simpson,Mark Brooks,Mark Brooks,Hamed Asadi,Hamed Asadi,Hamed Asadi,Teddy Y. Wu,Teddy Y. Wu,Darshan Shah,Darshan Shah,Tissa Wijeratne,Timothy Ang,Timothy Ang,Ferdinand Miteff,Christopher R Levi,Martin Krause,Timothy Harrington,Timothy Harrington,Kenneth Faulder,Kenneth Faulder,Brendan Steinfort,Brendan Steinfort,Peter L. Bailey,Henry Rice,Laetitia de Villiers,Rebecca Scroop,Wayne Collecutt,Andrew Wong,Alan Coulthard,Peter Barber,Ben McGuinness,Deborah Field,Henry Ma,Henry Ma,Winston Chong,Ronil V. Chandra,Christopher F. Bladin,Helen Brown,Kendal Redmond,David Leggett,Geoffrey Cloud,Anoop Madan,Neil Mahant,Bill O'Brien,John Worthington,Geoffrey Parker,Patricia Desmond,Mark W Parsons,Geoffrey A. Donnan,Stephen M. Davis,Extend-Ia Tnk Investigators +62 more
TL;DR: It is hypothesized that tenecteplase is non-inferior to alteplase in achieving reperfusion at initial angiogram, when administered within 4.5 h of ischemic stroke onset, in patients planned to undergo endovascular therapy.
Journal ArticleDOI
Outcomes of infrapopliteal endoluminal intervention for transatlantic intersociety consensus C and D lesions in patients with critical limb ischaemia.
TL;DR: It is reported that infrapopliteal percutaneous transluminal angioplasty stratified by TASC classification is a reasonable primary therapy for critical limb ischaemia for lesions classified as A, B or C.